| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/30/2014 | US8846612 Promotion of healthy catch-up growth |
| 09/30/2014 | CA2857543A1 Anti-obesity potential of calebin a |
| 09/30/2014 | CA2774073C Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance |
| 09/30/2014 | CA2670964C Use of composition for manufacture of medicant and method for inhibiting formation of body fat |
| 09/30/2014 | CA2586946C Nutrition containing fat blend |
| 09/30/2014 | CA2356706C Novel exendin agonist formulations and methods of administration thereof |
| 09/29/2014 | CA2847877A1 Prenylflavanone compounds for modulating diabetes |
| 09/25/2014 | WO2014153416A1 Compositions and methods for producing elevated and sustained ketosis |
| 09/25/2014 | WO2014153356A1 An in vivo intracellular reprogramming composition and method of making and using same |
| 09/25/2014 | WO2014153226A1 Arginine methyltransferase inhibitors and uses thereof |
| 09/25/2014 | WO2014153172A1 Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| 09/25/2014 | WO2014152993A1 Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| 09/25/2014 | WO2014152843A1 Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| 09/25/2014 | WO2014152789A1 Citrate containing beverage |
| 09/25/2014 | WO2014152338A1 Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| 09/25/2014 | WO2014152215A1 SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate |
| 09/25/2014 | WO2014152144A1 Muscarinic agonists |
| 09/25/2014 | WO2014152016A1 Leucine and nicotinic acid reduces lipid levels |
| 09/25/2014 | WO2014151962A1 Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides |
| 09/25/2014 | WO2014151899A1 Polycyclic estrogen receptor modulators and uses thereof |
| 09/25/2014 | WO2014151648A1 Treatment of autoimmune disease using helminthic parasites |
| 09/25/2014 | WO2014151258A1 Substituted pyridine derivatives useful as c-fms kinase inhibitors |
| 09/25/2014 | WO2014151247A1 Oxabicyclo [2.2.2] acid gpr120 modulators |
| 09/25/2014 | WO2014151128A1 Composition and method for treating neuropathy |
| 09/25/2014 | WO2014150772A1 Methods for treating or preventing fatty liver disease using ctrp3 |
| 09/25/2014 | WO2014150687A1 Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring |
| 09/25/2014 | WO2014150571A1 Reducing proinflammatory response |
| 09/25/2014 | WO2014150563A1 Activating adiponectin by casein hydrolysate |
| 09/25/2014 | WO2014150557A1 Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
| 09/25/2014 | WO2014150351A1 Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women |
| 09/25/2014 | WO2014150258A1 Compounds and uses thereof for the modulation of hemoglobin |
| 09/25/2014 | WO2014149987A1 Bicyclic pyrrole derivatives useful as agonists of gpr120 |
| 09/25/2014 | WO2014149280A1 Treatment of pets with sirtuin activators |
| 09/25/2014 | WO2014147141A1 Insulin dosing regimen |
| 09/25/2014 | WO2014147119A1 Silybin for the treatment of metabolic oxidative alterations in patients with non-alcoholic steatohepatitis (nash) |
| 09/25/2014 | WO2014147016A1 Ror gamma modulators |
| 09/25/2014 | WO2014146606A1 C-triaryl glucoside sglt-2 inhibitors |
| 09/25/2014 | WO2014146604A1 Fused ring compound having gpr40 receptor function regulating action |
| 09/25/2014 | WO2014146494A1 Β-aminocarbonyl compound, preparation method, pharmaceutical composition and use thereof |
| 09/25/2014 | WO2013082345A9 Aryl dihydropyridinones and piperidinones as mgat2 inhibitors |
| 09/25/2014 | US20140288266 Synthesis of Cyclosporin Analogs |
| 09/25/2014 | US20140288161 Urocortin-iii and uses thereof |
| 09/25/2014 | US20140287495 Methods of Inducing Differentiation of Stem Cells |
| 09/25/2014 | US20140287028 Use of Chemotherapeutic Agents |
| 09/24/2014 | EP2781600A1 Method for producing myo-inositol and myo-inositol derivative |
| 09/24/2014 | EP2781521A1 Novel spiroindoline compound, and medicinal agent comprising same |
| 09/24/2014 | EP2781516A2 New crystalline forms of the sodium salt of (4- {4- [5- ( 6 - trifluoromethyl - pyridin- 3 - ylamino ) - pyridin- 2 -yl]-phenyl} - cyclohexyl) -acetic acid |
| 09/24/2014 | EP2781217A1 ROR gamma modulators |
| 09/24/2014 | EP2780330A1 1-pyridazinyl-hydroxyimino- 3- phenyl- propanes as gpbar1 agonists |
| 09/24/2014 | EP2780029A1 Oral leptin formulations and uses thereof |
| 09/24/2014 | EP2779846A1 Use of whey protein micelles for infants at risk of obesity or diabetes |
| 09/24/2014 | EP2779845A1 Composition comprising chicory extract |
| 09/23/2014 | US8841261 Functional powdery product |
| 09/23/2014 | US8841252 Pharmaceutical formulation |
| 09/23/2014 | CA2750137C Compositions and methods for treating and preventing weight-related disorders in companion animals |
| 09/23/2014 | CA2651733C Guava leaf extract powder and method for production thereof |
| 09/23/2014 | CA2398995C Lipid hydrolysis therapy for atherosclerosis and related diseases |
| 09/18/2014 | WO2014146097A1 Compositions for treatment and/or prevention of autoimmune disorders |
| 09/18/2014 | WO2014146044A1 Administration of nicotinamide mononucleotide in the treatment of disease |
| 09/18/2014 | WO2014145683A1 Diabetes treatment |
| 09/18/2014 | WO2014145275A1 Methods for treatment of nephrotic syndrome and related conditions |
| 09/18/2014 | WO2014145118A1 Resorufin derivatives for treatment of oxidative stress disorders |
| 09/18/2014 | WO2014144895A1 Microcrystalline diketopiperazine compositions and methods |
| 09/18/2014 | WO2014144553A1 Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
| 09/18/2014 | WO2014143629A1 Bimatoprost for enhancement of leptin production |
| 09/18/2014 | WO2014143576A1 A composition comprising mannoheptulose for use in the treatment or prevention of overweight and obesity |
| 09/18/2014 | WO2014143125A1 Use of indole compounds for fat reduction and skin and soft tissue tightening |
| 09/18/2014 | WO2014142640A1 Improvements to the method for preparing hydroxocobalamin and the high-purity salts thereof |
| 09/18/2014 | WO2014142574A1 Pharmaceutical formulation comprising lipase inhibitor having increased dissolution rate and reduced side effects, and method for preparing same |
| 09/18/2014 | WO2014142535A1 Composition for treating diabetes, containing phytoncide-derived isoprenoid |
| 09/18/2014 | WO2014142521A1 Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
| 09/18/2014 | WO2014142363A1 Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
| 09/18/2014 | WO2014142322A1 Benzothiophene derivative |
| 09/18/2014 | WO2014142291A1 Hydrate of fluorine compound, and crystals thereof |
| 09/18/2014 | WO2014142290A1 Pyrazole-amide compound and medicinal uses therefor |
| 09/18/2014 | WO2014142273A1 Dihydropyridazine-3,5-dione derivative |
| 09/18/2014 | WO2014142182A1 Monoclonal antibody inhibiting enzymatic activity of endothelial lipase |
| 09/18/2014 | WO2014142127A1 Phenylxanthene derivative |
| 09/18/2014 | WO2014142084A1 METHOD FOR PRODUCING MONOCLONAL IgA ANTIBODY |
| 09/18/2014 | WO2014141165A1 Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production |
| 09/18/2014 | WO2014141124A1 Erk-pathway activating compound for preventing or treating leptin resistance |
| 09/18/2014 | WO2014140704A1 Indole compounds that activate ampk |
| 09/18/2014 | WO2014140402A1 Use of derivatives with c-o-p bonds in patients with renal failure |
| 09/18/2014 | WO2014140284A1 Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
| 09/18/2014 | WO2014140241A1 Pyridine derivatives as dgat-1 inhibitors |
| 09/18/2014 | WO2014140186A1 Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases |
| 09/18/2014 | WO2014139472A1 Compositions and methods of using islet neogenesis peptides and analogs thereof |
| 09/18/2014 | WO2014139469A1 Ornithine- or aspartate-containing compositions and the uses thereof |
| 09/18/2014 | WO2014139447A1 Crystal form a of (1s)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-d-glucose and preparation method and use thereof |
| 09/18/2014 | WO2014139388A1 Novel indole derivatives useful as anti-diabetic agents |
| 09/18/2014 | WO2014139182A1 Compositions and methods of using islet neogenesis peptides and analogs thereof |
| 09/18/2014 | WO2014139168A1 Preparation process of polymeric microspheres |
| 09/18/2014 | WO2014139063A1 Black medical soybean food obtained by immersing black soybeans in life-cultivating and health-care vinegar medical tea to carry out biological fermentation |
| 09/18/2014 | WO2014139008A1 Small molecule modulators of pcsk9 and methods of use thereof |
| 09/18/2014 | WO2014138937A1 A growth hormone secretagogue receptor based protein, nucleic acids and methods and uses thereof |
| 09/18/2014 | WO2014138920A1 Method for extracting organic solids and oil from marine organisms enriched with astaxanthin |
| 09/18/2014 | WO2014138791A1 Transgenic non-human organisms with non-functional tspo genes |
| 09/18/2014 | US20140275545 8-carboxamido-2,6-methano-3-benzazocines |
| 09/18/2014 | US20140275479 Specific binding agents of human angiopoeitin-2 |
| 09/18/2014 | US20140275225 Modulators of pharmacological agents |